Ameliorating effect of eugenol on hyperglycemia by attenuating the key enzymes of glucose metabolism in streptozotocin-induced diabetic rats.
Epidemiological studies have demonstrated that diabetes mellitus is a serious health burden for both governments and healthcare providers. This study was hypothesized to evaluate the antihyperglycemic potential of eugenol by determine the activities of key enzymes of glucose metabolism in streptozotocin (STZ)-induced diabetic rats. Diabetes was induced into male albino Wistar rats by intraperitoneal administration of STZ (40 mg/kg body weight (b.w.)). Eugenol was administered to diabetic rats intragastrically at 2.5, 5, and 10 mg/kg b.w. for 30 days. The dose 10 mg/kg b.w. significantly reduced the levels of blood glucose and glycosylated hemoglobin (HbA1c) and increased plasma insulin level. The altered activities of the key enzymes of carbohydrate metabolism such as hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, fructose-1,6-bisphosphatase, and liver marker enzymes (AST, ALT, and ALP), creatine kinase and blood urea nitrogen in serum and blood of diabetic rats were significantly reverted to near normal levels by the administration of eugenol. Further, eugenol administration to diabetic rats improved body weight and hepatic glycogen content demonstrated the antihyperglycemic potential of eugenol in diabetic rats. The present findings suggest that eugenol can potentially ameliorate key enzymes of glucose metabolism in experimental diabetes, and it is sensible to broaden the scale of use of eugenol in a trial to alleviate the adverse effects of diabetes.
Subramani
S
Srinivasan
Gajendren
G
Sathish
Mahadevan
M
Jayanthi
Jayachandran
J
Muthukumaran
Udaiyar
U
Muruganathan
Vinayagam
V
Ramachandran
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002241:Carbohydrates / Q000652:urine; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology* / Q000652:urine; D004327:Drinking Behavior / Q000187:drug effects; D005054:Eugenol / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D005247:Feeding Behavior / Q000187:drug effects; D006597:Fructose-Bisphosphatase / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology* / Q000652:urine; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011770:Pyruvate Kinase / Q000378:metabolism; D051381:Rats; D013311:Streptozocin
D001786:Blood Glucose; D002241:Carbohydrates; D005054:Eugenol; D006597:Fructose-Bisphosphatase; D005947:Glucose; D005952:Glucose-6-Phosphatase; D005954:Glucosephosphate Dehydrogenase; D006442:Glycated Hemoglobin; D006003:Glycogen; D006593:Hexokinase; D007328:Insulin; D011770:Pyruvate Kinase; D013311:Streptozocin